Related Experiment Video
Updated: Sep 10, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Preferential Sensitivity of the EGFR L858M/L861R Mutation to Second-Generation EGFR Tyrosine Kinase Inhibitors in
Chaelin Lee1, Sheehyun Kim2, Soyeon Kim1,3
1Cancer Research Institute, Seoul National University, Seoul, Korea.
Purpose:
Non-small cell lung cancer (NSCLC) frequently harbors targetable EGFR mutations. However, rare variants such as EGFR L858M or L861R remain poorly characterized. This study aimed to elucidate the oncogenic potential and EGFR tyrosine kinase inhibitors (TKIs) sensitivity of the EGFR L858M/L861R mutation to inform personalized treatment strategies.
Materials And Methods:
Tumor samples from a NSCLC patient were analyzed using targeted panel sequencing and confirmed with the FoundationOne Liquid CDx assay. EGFR-mutant constructs, including L858M, L858R, L861R, L861Q, L858M/L861R, and L858R/L861Q, were generated and transduced into various cell lines. Cell viability, immunoblot, and soft agar colony formation assays were conducted to assess the oncogenicity and drug sensitivity, while computational protein modeling and docking simulations evaluated the drug-binding affinities of EGFR TKIs.
Results:
Ba/F3 cells expressing the EGFR L858M/L861R mutation exhibited robust IL-3-independent proliferation accompanied by markedly increased EGFR phosphorylation, while NIH-3T3 cells showed anchorage-independent colony formation. Compared to other mutations, cells expressing EGFR L858M/L861R mutation were less sensitive to first-generation EGFR TKIs (gefitinib, erlotinib) and third-generation EGFR TKIs (osimertinib, lazertinib), whereas second-generation EGFR TKIs (afatinib, poziotinib) demonstrated potent inhibitory effects. Computational modeling revealed a narrower drug-binding efficiency of first-generation inhibitors.
Conclusion:
The EGFR L858M/L861R mutation drives strong oncogenic signaling and exhibits preferential sensitivity to second-generation EGFR TKIs. These findings underscore the importance of accurate molecular diagnosis for guiding effective, personalized therapeutic strategies in NSCLC.
Insights
The rare EGFR L858M/L861R mutation in non-small cell lung cancer drives oncogenic signaling. Second-generation EGFR tyrosine kinase inhibitors show potent activity against this mutation.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) often has targetable EGFR mutations.
- Rare EGFR variants like L858M and L861R are not well understood.
- Personalized treatment for NSCLC requires characterizing rare EGFR mutations.
Purpose of the Study:
- To investigate the oncogenic potential of the EGFR L858M/L861R mutation.
- To determine the sensitivity of this mutation to various EGFR tyrosine kinase inhibitors (TKIs).
- To inform personalized treatment strategies for NSCLC patients with rare EGFR mutations.
Main Methods:
- EGFR-mutant constructs (L858M, L858R, L861R, L861Q, L858M/L861R, L858R/L861Q) were generated and transduced into cell lines.
- Assays for cell viability, immunoblotting, and soft agar colony formation assessed oncogenicity and drug sensitivity.
- Computational modeling evaluated drug-binding affinities of EGFR TKIs.
Main Results:
- EGFR L858M/L861R mutation induced IL-3-independent proliferation and EGFR phosphorylation in Ba/F3 cells.
- NIH-3T3 cells with this mutation showed anchorage-independent colony formation.
- Cells with EGFR L858M/L861R were less sensitive to first- and third-generation TKIs but sensitive to second-generation TKIs (afatinib, poziotinib).
Conclusions:
- The EGFR L858M/L861R mutation strongly drives oncogenic signaling in NSCLC.
- This mutation shows a preference for second-generation EGFR TKIs.
- Accurate molecular diagnosis is crucial for effective personalized NSCLC therapy.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
